Document Detail


Update on fondaparinux: role in management of thromboembolic and acute coronary events.
MedLine Citation:
PMID:  20184552     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anticoagulants are the mainstay of treatment of venous thromboembolic and acute coronary events. Improvements of new over established anticoagulants are targeted to achieve more favorable pharmacokinetics, minimal hemorrhagic side effects, a predictable dose response that obviates the need for coagulation monitoring, and more appropriate dose selection for the indication of interest. New parenteral anticoagulants are free of the complications of HIT, can be selected so that they are safe in patients with impaired renal or hepatic function, and can be administered once daily without the need for coagulation monitoring. Drug development has been focused on two key targets: factor Xa and factor IIa (thrombin). Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially available for clinical use. It has been approved for the prevention of venous thromboembolism in patients undergoing orthopedic surgery, abdominal surgery and for the initial therapy of deep venous thrombosis and venous thromboembolism. Fondaparinux sodium injection has been accepted for priority review by the United States Food and Drug Administration based on positive results from two pivotal, Phase III trials (OASIS 5 and 6) that evaluated its role in the treatment of a broad spectrum of patients with acute coronary syndromes (ACS). In this article, we review the available literature that provides evidence for the efficacy of fondaprinux in management of thromboembolic disease as well as acute coronary syndromes.
Authors:
Tulsi Sharma; Pankaj Mehta; Ajeet Gajra
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular & hematological agents in medicinal chemistry     Volume:  8     ISSN:  1875-6182     ISO Abbreviation:  Cardiovasc Hematol Agents Med Chem     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-28     Completed Date:  2010-08-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266881     Medline TA:  Cardiovasc Hematol Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  96-103     Citation Subset:  IM    
Affiliation:
Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, NY, USA. GajraA@upstate.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Anticoagulants / therapeutic use*
Coronary Disease / drug therapy*
Humans
Polysaccharides / therapeutic use*
Thromboembolism / drug therapy*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Polysaccharides; 0/fondaparinux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nitric Oxide and Oral Diseases: Can we Talk about it?
Next Document:  Status of bi- and multi-nuclear platinum anticancer drug development.